论文部分内容阅读
目的探讨雄激素受体(AR)在PCA中的表达和意义。方法应用免疫组化ELIVISON法,检测45例 PCA和10例前列腺增生组织标本中AR的表达,并探讨AR蛋白表达与PCA分期、分级、术前PSA、内分泌治疗效果及预后的关系。结果 AR在PCA和前列腺增生中阳性表达率分别为90%和93.3%,阳性表达率和表达程度无显著性差异(P>0.05);D期和A-C期PCA中阳性表达率分别为100%和87.5%,无显著差异(P>0.05), 但D期PCA AR阳性表达程度显著增强(P<0.05);GLEASON评分≤7和GLEASON评分>7PCA中阳性表达率分别为85.7%和100%,无显著差异(P>0.05),但低分化PCA(GLEASON评分>7)AR阳性表达程度显著增强(P <0.05);PSA≤10NG/ML和PSA>10NG/ML PCA中阳性表达率分别为80%和97.1%,阳性表达率和表达程度无显著性差异(P>0.05);在内分泌治疗有效和无效PCA中阳性表达率分别为87.5%和90.9%,阳性表达率和表达程度无显著性差异(P>0.05)。结论 AR阳性表达程度与PCA分期、分级有关,对判断PCA生物学行为有参考价值。
Objective To investigate the expression and significance of androgen receptor (AR) in PCA. Methods The immunohistochemical ELIVISON method was used to detect the expression of AR in 45 cases of PCA and 10 cases of benign prostatic hyperplasia. The relationship between AR protein expression and PCA staging, grading, preoperative PSA, endocrine therapy and prognosis were analyzed. Results The positive expression rates of AR in PCA and BPH were 90% and 93.3%, respectively. There was no significant difference between the positive expression rate and the expression level of AR (P> 0.05). The positive rates of PCNA in stage D and stage AC were respectively (P <0.05). However, the positive expression of PCA-AR in stage D was significantly increased (P <0.05). The positive expression of PCA-AR in stage D was less than 7 and GLEASON score was> 7PCA (P> 0.05). However, the positive expression of AR in poorly differentiated PCA (GLEASON score> 7) was significantly increased (P <0.05) ML and PSA> 10NG / ML PCA were 80% and 97.1%, respectively, with no significant difference between the two groups (P> 0.05). The positive rates of expression in PCA with or without endocrine therapy The rates were 87.5% and 90.9% respectively, with no significant difference between the positive expression rate and the expression level (P> 0.05). Conclusion The positive expression of AR is related to PCA staging and grading, which is of reference value for judging the biological behavior of PCA.